Company Insights

PSNL customer relationships

Explore interactive graphBrowse insights index
PSNL customer relationship map

Personalis (PSNL) — Customer Map and Commercial Risks for Investors

Personalis is a precision oncology services company that monetizes by selling advanced genomic testing and analytics to biopharma, diagnostics firms, government population programs and payers, plus licensing select IP; revenue comes primarily from recurring services contracts and project work tied to clinical trials and MRD partnerships. This profile creates a high-margin growth opportunity when MRD adoption scales, but it also produces concentration and timing risk because a handful of large counterparties account for the majority of sales. For a concise, structured view of counterparty exposure and operational constraints, visit https://nullexposure.com/.

How Personalis runs its business and what drives revenue

Personalis operates a single reportable segment of advanced cancer genomic tests and services, selling to pharma, diagnostics companies, universities, non-profits, government entities and patients. According to the company’s 2024 Form 10-K, the U.S. accounts for 96% of revenue, and the top five customers, including the VA MVP, Moderna and Natera, represented 81% of revenue in 2024, underscoring material revenue concentration (10-K, FY2024). The company’s commercial mix is shifting from low-value project work to higher-value molecular residual disease (MRD) partnerships, which drives strategic emphasis on partnerships and payer coverage.

For a practical investor briefing and deeper counterparty analysis, see https://nullexposure.com/.

The customer roster — plain-English summaries with sources

U.S. Department of Veterans Affairs Million Veterans Program (VA MVP)

Personalis provides whole genome sequencing services under contract to the VA MVP, and historically the VA program accounted for a meaningful share of revenue — 9% of revenue in 2024 and 13% in 2023 per the company’s 2024 Form 10-K; more recent disclosures combine VA MVP with enterprise sales when reporting population sequencing revenue (Personalis 2024 10-K; company press releases, FY2026).

Natera, Inc. (NTRA)

Personalis has an agreement to provide advanced tumor analysis for use in Natera’s MRD offering, and that partnership historically generated a substantial portion of revenue in the enterprise sales category; the company reported planned revenue shifts away from lower-value project work that produced a near $20 million year-over-year decline tied to Natera as Personalis reoriented toward MRD engine growth (Personalis 2024 10-K; Q4 2025 earnings commentary, FY2026).

Moderna / ModernaTX, Inc. (MRNA)

Personalis supplies genomic testing in Moderna’s clinical trials for personalized cancer therapies and recorded significant customer deposits tied to Moderna in 2023; the company also disclosed that conclusion of Moderna melanoma trial enrollment contributed a roughly $10 million revenue decline from 2024 as trials wound down (Personalis 2024 10-K; Q4 2025 earnings commentary, FY2026).

Merck Sharp & Dohme LLC (MRK)

After Merck became a related party in December 2024, Personalis invoiced approximately $2.0 million for genomic testing services under a Master Agreement, and Merck is cited among customers that influence timing and pace of orders (Personalis 2024 10-K; company press releases, FY2026).

Medicare (payer coverage)

Medicare announced reimbursement for Personalis’ NeXT Personal MRD test when used for surveillance of early- to mid-stage non‑small cell lung cancer, creating immediate commercial implication for revenue mix and pricing power in the clinical market (news reports, StockTwits and OncoDaily, March 2026).

What the constraints tell investors about operating posture

  • Concentration and criticality. The 10-K shows the top five customers account for 81% of 2024 revenue, making Personalis commercially concentrated and dependent on a small set of high-value partners (10-K, FY2024). That concentration increases revenue volatility tied to contract renewals and trial timelines.
  • Contracting posture — short-term and project-based with strategic anchors. Annual task orders were $7.5 million in both 2023 and 2024, signaling a mix of short-term task work alongside larger trial and population contracts. At the same time, Personalis uses targeted licensing deals (e.g., a non‑exclusive license to Foresight under the S&L Agreement) that produce small royalty streams rather than broad recurring licensing revenue.
  • Counterparty mix and maturity. Customers span government (explicitly the VA MVP), very large enterprises (large oncology-focused pharma), non-profits, individuals and payers; this breadth gives diversified demand sources but retains single-customer exposure at the top. Working relationships with major pharma and diagnostics businesses indicate commercial maturity in the clinical-trial segment.
  • Geographic concentration. The business is substantially U.S.-centric (96% of revenue in 2024), which concentrates regulatory, payer and reimbursement risk domestically.
  • Service-led segment dynamics. Personalis operates one reportable segment focused on services, so margin expansion depends on scaling higher-value MRD partnerships and improving utilization across lab operations rather than product diversification.

Constraints explicitly cited in filings include a licensing agreement that grants Foresight a non-exclusive worldwide license in exchange for low single-digit royalties (company S&L Agreement), and the documented short-term task order levels noted above (10-K excerpts).

Investment takeaways and checklist

  • Positive: payer coverage for NeXT Personal MRD and deep pharma partnerships create a scalable revenue pathway if MRD adoption accelerates into routine clinical surveillance (news, March 2026).
  • Negative: acute customer concentration and U.S. revenue concentration mean quarter-to-quarter results hinge on a few counterparties and trial timelines, as demonstrated by the sizable year-over-year swings tied to Natera and Moderna project conclusions (10-K and earnings commentary, FY2024–FY2026).
  • Watch list for near-term catalysts: cadence of MRD orders from biopharma customers, incremental Medicare/private payer adoption beyond lung cancer, and renewal/expansion of VA MVP and Natera contracts.

For a compact competitive and counterparty risk dashboard tailored for investors and operators, visit https://nullexposure.com/.

Persona-specific call-to-action: institutional investors and operational risk managers should prioritize revenue-concentration stress tests, contract expiration timelines, and payer-adoption scenarios when modeling Personalis’ path to scaled MRD revenue.